Categories: News

JPMorgan ETFs (Ireland) ICAV: Change of Index for various sub-funds

DUBLIN, Ireland, Jan. 15, 2021 (GLOBE NEWSWIRE) —

JPMorgan ETFs (Ireland) ICAV

Notice of Index Change

Please note that effective 29 January 2021 the following Index Tracking Sub-Funds will change Index in order to retain the current index exit maturity rules and the Sub-Fund Supplements will be updated accordingly. There will be no change to how the Sub-Funds are managed in practice.

JPMorgan ETFs (Ireland) ICAV – BetaBuilders US Treasury Bond UCITS ETF
JPMorgan ETFs (Ireland) ICAV – BetaBuilders US Treasury Bond 1-3 yr UCITS ETF
JPMorgan ETFs (Ireland) ICAV – BetaBuilders UK Gilt 1-5 yr UCITS ETF
JPMorgan ETFs (Ireland) ICAV – BetaBuilders EUR Govt Bond UCITS ETF
JPMorgan ETFs (Ireland) ICAV – BetaBuilders EUR Govt Bond 1-3 yr UCITS ETF

To view the full details, please paste the following URL into the address bar of your browser.

https://am.jpmorgan.com/content/dam/jpm-am-aem/emea/regional/en/supplemental/notice-to-shareholders/jpm-etfs-ireland-icav-index-changes-en.pdf

Enquiries:

JPMorgan
Annabel Dow
annabel.s.dow@jpmorgan.com
+44 207 7428379

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Staff

Recent Posts

Is The DEA in Systemic Collapse: Corruption, Constitutional Violations, and a Seven-Year War Against Marijuana Medical Science

The DEA was created to combat cartel trafficking, protect public health, and ensure researchers have…

8 hours ago

Prime Medicine Announces The New England Journal of Medicine Publication of PM359 Clinical Data for the Treatment of Chronic Granulomatous Disease

CAMBRIDGE, Mass., Dec. 07, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology…

8 hours ago

Secura Bio Presents Extended Follow Up Analyses from Phase 2 PRIMO Trial in Patients with Relapsed/Refractory peripheral T-cell lymphoma at the 2025 American Society of Hematology Meeting

Longer-term analyses reinforce duvelisib’s activity across treatment-experienced PTCL populations, including patients with ≥3 prior lines…

8 hours ago